Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial

Hannah S. Van Meurs, Parvin Tajik*, Michel H.P. Hof, Ignace Vergote, Gemma G. Kenter, Ben Willem J. Mol, Marrije R. Buist, Patrick M. Bossuyt

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

75 Citations (Scopus)

Fingerprint Dive into the research topics of 'Which patients benefit most from primary surgery or neoadjuvant chemotherapy in stage IIIC or IV ovarian cancer? An exploratory analysis of the European Organisation for Research and Treatment of Cancer 55971 randomised trial'. Together they form a unique fingerprint.

Medicine & Life Sciences